帕金森病预防试验中的结局评估:临床与数字指标的应用价值
该研究基于专家意见综述前驱期帕金森病细微运动特征的存在与时间进程,评估临床特征、患者报告结局、数字标志物和临床诊断等结局指标在预防试验中用于患者分层、中间结局和临床相关终点(包括表型转化)的价值,认为运动特征演变已有相当进展,数字指标有助提高测量精度并可在自然环境中使用,未来应推进数字传感器技术与分析方法并开发在临床试验中实施现有方法(尤其确定帕金森病临床诊断)的方法。
要点
- 前驱期帕金森病存在不足以诊断的细微临床体征,可在预防试验中测量。
- 结局指标包括临床特征、患者报告结局、数字标志物和临床诊断。
- 数字指标有助提高测量精度并可在诊所外自然环境使用。
核心结论
- 对诊断前帕金森病运动特征演变的认识已取得相当进展,数字指标有助提高测量精度并可在自然环境使用,未来应推进数字传感器技术与分析并开发在临床试验中实施现有方法(尤其确定帕金森病临床诊断)的方法。
研究设计与样本
- 基于专家意见的文献综述,评估前驱期帕金森病细微运动特征的存在与时间进程,以规划可能的临床试验。
主要发现
- 在患者分层、中间结局和临床相关终点(包括表型转化)的背景下考虑了临床特征测量、患者报告结局、数字标志物和临床诊断等结局。
- 数字指标在测量精度方面有相当进展,并可在诊所外自然环境使用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The prodromal phase of Parkinson disease (PD) is accompanied by subtle clinical signs that are not sufficient for diagnosis but could potentially be measured in the context of clinical trials of therapies intended to delay or prevent more definitive clinical features. The objective of this study was to review the available literature on the presence and time course of subtle motor features in prodromal PD in the context of planning for possible clinical trials. METHODS: We reviewed the available literature based on expert opinion. We considered a range of outcomes including measurement of clinical features, patient-reported outcomes, digital markers, and clinical diagnosis. RESULTS: We considered these features and measures in the context of patient stratification, intermediate outcomes, and clinically relevant end points, including phenoconversion. DISCUSSION: Substantial progress has been made in understanding how motor features evolve in the period immediately before a PD diagnosis. Digital measures hold substantial progress for measurement precision and may be additionally relevant because they can be used in naturalistic environments outside the clinic. Future studies should focus on advancing digital sensor technology and analysis and developing methods to implement available methods, particularly determination of a clinical diagnosis of PD, in a clinical trial context.
引用
- Mirelman A, Siderowf A, Chahine L, et al. Outcome Assessment in Parkinson Disease Prevention Trials: Utility of Clinical and Digital Measures. Neurology. 2022. PMID: 35970590. doi:10.1212/WNL.0000000000200236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。